The Safety and Effectiveness of SEL 212 in Chronic Refractic Disorders

There are two major reports on gout that were interesting LB late-breaking OO to the safety and efficacy of SEL 212 in patients with chronic refractic out. data was the same in all groups so even if there was a fault in how the data was collected the results showed that the groups were not different as far as mace events I don't know. A newer molecule called AR-882 is a year at one inhibitor that's in development OP 0295 the 12 week double-blind placebo control study phase 2B again this inhibits your at one a little bit like you less centarad but it's safer, they say.